Sign in

    Naomi Kumagai

    Research Analyst at Mitsubishi UFJ Morgan Stanley Securities

    Naomi Kumagai's questions to SHIONOGI & CO (SGIOY) leadership

    Naomi Kumagai's questions to SHIONOGI & CO (SGIOY) leadership • FY 2022

    Question

    Naomi Kumagai from Mitsubishi UFJ Morgan Stanley Securities asked about the delay in Xocova's approval in Korea and sought to understand the key drivers behind the forecasted 10% increase in HIV royalty revenue.

    Answer

    Toshinobu Iwasaki, Executive Officer, attributed the Korean approval delay to a slowdown in the regulatory process following the easing of the country's emergency state, similar to the situation in China. For HIV royalties, he confirmed that Dovato and Cabenuva are the primary growth drivers, with Apretude also performing ahead of plan and expected to contribute.

    Ask Fintool Equity Research AI

    Naomi Kumagai's questions to SHIONOGI & CO (SGIOY) leadership • Q3 2022

    Question

    Naomi Kumagai of Mitsubishi UFJ Morgan Stanley asked if the Xocova supply to Korea would be a government purchase and sought to clarify if the remaining JPY10 billion in the COVID-19 product sales forecast would come from Korea, assuming China sales would be booked in the next fiscal year. She also asked for an update on the submission and approval timeline in China.

    Answer

    An Unidentified Speaker stated that the purchase terms for Xocova in Korea are still under active negotiation. Regarding the sales forecast, they clarified that revenue from China could potentially be booked in the current fiscal year if the amount is significant, despite the different fiscal calendar. They also noted that the submission process in China is proceeding slightly ahead of projections.

    Ask Fintool Equity Research AI

    Naomi Kumagai's questions to SHIONOGI & CO (SGIOY) leadership • Q1 2022

    Question

    Naomi Kumagai from Mitsubishi UFJ Morgan Stanley asked about the new antifungal agent olorofim, inquiring about the objective of its Phase 3 study, its mechanism of action (MoA), and its key differentiators compared to existing drugs.

    Answer

    Ryuichi Kiyama, Senior Executive Officer, explained that the Phase 3 study is part of a program to gather data for global registrations. John Keller, SVP of R&D, elaborated that olorofim has a distinct MoA targeting dihydroorotate dehydrogenase, which is expected to be effective against infections that are increasingly resistant to current therapies.

    Ask Fintool Equity Research AI